ZFIN ID: ZDB-FISH-150901-19290
Fish name: knu3Tg
Genotype: knu3Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by knu3Tg
Human Disease Conditions Citations
glioblastoma cancer xenotransplantation Pudelko et al., 2018
GENE EXPRESSION
Gene expression in knu3Tg
RNA expression
Expressed Gene Structure Conditions Figures
atoh1a standard conditions Fig 1 with image from Belzunce et al., 2020
atoh1b standard conditions Fig 1 with image from Belzunce et al., 2020
cxcr4b standard conditions Fig. 1 with imageFig. 2 with imageFig. 3 with image from Roussigné et al., 2009
cxcr5 control Fig. S2 with image from Kizil et al., 2012
physical alteration: anatomical structure Fig. S2 with image from Kizil et al., 2012
dla standard conditions Fig. 2 with image from Cau et al., 2008
dlb standard conditions Fig. 3 with image from Dyer et al., 2014
Fig. 2 with image from Cau et al., 2008
dld standard conditions Fig. 2 with image from Cau et al., 2008
flt1 standard conditions Fig. 5 with image from Krueger et al., 2011
isl1a standard conditions Fig. 4 with imageFig. 5 with image from Cau et al., 2008
kctd12.1 standard conditions Fig. 1 with image from Roussigné et al., 2009
lhx3 standard conditions Fig. 1 with image from Cau et al., 2008
map2k5 standard conditions Fig. S11 from Jo et al., 2017
neurod1 standard conditions Fig. 4 with image from Quillien et al., 2011
neurog1 standard conditions Fig. 5 with image from Dyer et al., 2014
Fig. 2 with image from Roussigné et al., 2009
otx5 standard conditions Fig. 4 with image from Quillien et al., 2011
pou4f1 standard conditions Fig. 1 with image from Roussigné et al., 2009
vegfaa standard conditions Fig. 1 with image from Madelaine et al., 2017
PHENOTYPE
Phenotype in knu3Tg
Phenotype Conditions Figures
brain central nervous system tumor increased amount, abnormal cancer xenotransplantation Fig. 1 from Pudelko et al., 2018
habenula determination of left/right symmetry disrupted, abnormal chemical treatment: pharmaceutical Fig. 6 with image from Roussigné et al., 2009
habenula neurogenesis delayed, abnormal chemical treatment: pharmaceutical Fig. 6 with image from Roussigné et al., 2009
habenula neurogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 6 with image from Roussigné et al., 2009
neural tube morphology, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Araya et al., 2014
neuron amount, normal control Fig. 4 with image from Gribble et al., 2007
neuron amount, normal chemical treatment: Cyclopamine Fig. 4 with image from Gribble et al., 2007
nodal signaling pathway involved in determination of left/right asymmetry disrupted, abnormal chemical treatment: pharmaceutical Fig. 6 with image from Roussigné et al., 2009
primary neuron proliferative, abnormal chemical treatment: messenger RNA Fig. 6 from Rodríguez-Aznar et al., 2013
proliferative region mislocalised, abnormal chemical treatment: messenger RNA Fig. 6 from Rodríguez-Aznar et al., 2013
re-entry into mitotic cell cycle increased occurrence, abnormal chemical treatment: messenger RNA Fig. 6 from Rodríguez-Aznar et al., 2013
regulation of neural precursor cell proliferation decreased process quality, abnormal chemical treatment: messenger RNA Fig. 6 from Rodríguez-Aznar et al., 2013

CITATIONS  (85)